Impact Biomedical IBO
NYSE IBO
$0.46 -0.03 (-7.15%)
As of: Sep 10, 2026 · 3:57 PM EDT

Impact Biomedical (IBO) Gross Profit (2025 - 2026)

Impact Biomedical's (IBO) quarterly Gross Profit came in at $2000.0 in Q2 2026, down 66.67% on a YoY basis from $6000.0 in Q2 2025, and down 88.24% quarter-over-quarter from $17000.0 in Q3 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Impact Biomedical (IBO) Gross Profit (2025 - 2026) Analysis & Trends

Impact Biomedical (IBO) has reported Gross Profit for 2 consecutive years, with $2000.0 the latest figure, recorded in Q2 2026.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Impact Biomedical 49.63 Mn 49.62 Mn 2,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2,000.00
Sep 30, 2025 17,000.00
Jun 30, 2025 6,000.00